122 related articles for article (PubMed ID: 6488441)
1. Pharmacokinetic study of VM26 given as a prolonged IV infusion to ovarian cancer patients.
Rossi C; Zucchetti M; Sessa C; Urso R; Mangioni C; D'Incalci M
Cancer Chemother Pharmacol; 1984; 13(3):211-4. PubMed ID: 6488441
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of teniposide in patients with ovarian cancer.
D'Incalci M; Rossi C; Sessa C; Urso R; Zucchetti M; Farina P; Mangioni C
Cancer Treat Rep; 1985 Jan; 69(1):73-7. PubMed ID: 3967261
[TBL] [Abstract][Full Text] [Related]
3. Combination chemotherapy of the epipodophyllotoxin derivatives, teniposide and etoposide. A pharmacodynamic rationale?
Allen LM; Tejada F; Okonmah AD; Nordqvist S
Cancer Chemother Pharmacol; 1982; 7(2-3):151-6. PubMed ID: 7083456
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of Teniposide (VM26) and etoposide (VP16-213) in children with cancer.
Evans WE; Sinkule JA; Crom WR; Dow L; Look AT; Rivera G
Cancer Chemother Pharmacol; 1982; 7(2-3):147-50. PubMed ID: 7083455
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of teniposide (VM 26) after IV administration in serum and malignant ascites of patients with ovarian carcinoma.
Canal P; Bugat R; Michel C; Roche H; Soula G; Combes PF
Cancer Chemother Pharmacol; 1985; 15(2):149-52. PubMed ID: 4017164
[TBL] [Abstract][Full Text] [Related]
6. [The toxicity of massive dosis of VM26 (4-demethyl-epipodophyllotoxin-beta-D-thenylidene glucoside). A contribution to the therapy of advanced ovarian cancer (author's transl)].
Jankowski RP; Vahrson H
Med Klin; 1977 Dec; 72(49):2122-6. PubMed ID: 337083
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of continuous infusion of methotrexate and teniposide in pediatric cancer patients.
Rodman JH; Sunderland M; Kavanagh RL; Ochs J; Yalowich J; Evans WE; Rivera GK
Cancer Res; 1990 Jul; 50(14):4267-71. PubMed ID: 2194652
[TBL] [Abstract][Full Text] [Related]
8. Clinical pharmacodynamics of continuous infusion teniposide: systemic exposure as a determinant of response in a phase I trial.
Rodman JH; Abromowitch M; Sinkule JA; Hayes FA; Rivera GK; Evans WE
J Clin Oncol; 1987 Jul; 5(7):1007-14. PubMed ID: 3598607
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of high-dose teniposide.
Holthuis JJ; de Vries LG; Postmus PE; van Oort WW; Verleun H; Hulshoff A; Sleijfer DT; Mulder NH
Cancer Treat Rep; 1987 Jun; 71(6):599-603. PubMed ID: 3581097
[TBL] [Abstract][Full Text] [Related]
10. Teniposide (VM26) disposition in children with leukemia.
Sinkule JA; Stewart CF; Crom WR; Melton ET; Dahl GV; Evans WE
Cancer Res; 1984 Mar; 44(3):1235-7. PubMed ID: 6581866
[TBL] [Abstract][Full Text] [Related]
11. Teniposide in the treatment of small-cell lung cancer: the influence of prior chemotherapy.
Giaccone G; Donadio M; Bonardi G; Testore F; Calciati A
J Clin Oncol; 1988 Aug; 6(8):1264-70. PubMed ID: 2842464
[TBL] [Abstract][Full Text] [Related]
12. A case of small cell lung cancer successfully treated with VM26.
Suga J; Saijo N; Shinkai T; Eguchi K; Sasaki Y; Sakurai M; Sano T; Tamura T; Morinaga S
Jpn J Clin Oncol; 1986 Jun; 16(2):123-8. PubMed ID: 3016377
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics and efficacy of i.v. and i.p. VM26 chemotherapy in mice bearing Krebs II ascitic tumors.
Canal P; Bugat R; Rokoszak B; Berg D; Soula G; Roche H
Eur J Cancer Clin Oncol; 1986 Jul; 22(7):765-71. PubMed ID: 3770034
[TBL] [Abstract][Full Text] [Related]
14. Activity and pharmacokinetics of teniposide in Lewis lung carcinoma-bearing mice.
Broggini M; Colombo T; D'Incalci M
Cancer Treat Rep; 1983 Jun; 67(6):555-9. PubMed ID: 6861161
[TBL] [Abstract][Full Text] [Related]
15. Cyclosporin A as a multidrug-resistant modulator in patients with renal cell carcinoma treated with teniposide.
Toffoli G; Sorio R; Gigante M; Corona G; Galligioni E; Boiocchi M
Br J Cancer; 1997; 75(5):715-21. PubMed ID: 9043030
[TBL] [Abstract][Full Text] [Related]
16. Single- and double-strand DNA breakage and repair in human lung adenocarcinoma cells exposed to etoposide and teniposide.
Long BH; Musial ST; Brattain MG
Cancer Res; 1985 Jul; 45(7):3106-12. PubMed ID: 3839166
[TBL] [Abstract][Full Text] [Related]
17. Uptake and binding of teniposide (VM26) in Krebs II ascites cells.
Hamza M; Canal P; Bugat R; Soula G; Douste-Blazy L
Biochem Pharmacol; 1987 May; 36(10):1599-603. PubMed ID: 3109424
[TBL] [Abstract][Full Text] [Related]
18. Etoposide (VP16) and teniposide (VM26): novel anticancer drugs, strongly mutagenic in mammalian but not prokaryotic test systems.
Gupta RS; Bromke A; Bryant DW; Gupta R; Singh B; McCalla DR
Mutagenesis; 1987 May; 2(3):179-86. PubMed ID: 3325741
[TBL] [Abstract][Full Text] [Related]
19. DNA breakage in human lung carcinoma cells and nuclei that are naturally sensitive or resistant to etoposide and teniposide.
Long BH; Musial ST; Brattain MG
Cancer Res; 1986 Aug; 46(8):3809-16. PubMed ID: 3015377
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of VP16-213 given by different administration methods.
D'Incalci M; Farina P; Sessa C; Mangioni C; Conter V; Masera G; Rocchetti M; Pisoni MB; Piazza E; Beer M; Cavalli F
Cancer Chemother Pharmacol; 1982; 7(2-3):141-5. PubMed ID: 7083454
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
